Adagrasib - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Adagrasib

Brand Name:

Krazati

Strength:

200mg

HCPCS:

SEER*Rx Category:

Immunotherapy

Major Drug Class:

RAS Inhibitor

Minor Drug Class:

KrAS G12C

Oral (Y/N):

Yes

FDA Approval Year:

2022

FDA Discontinuation Year:

CMS Effective Date:

CMS Discontinuation Date:

Status:

In Use